Curis INC (CRIS) — SEC Filings

Q: What are the key financial highlights for Curis INC?

Key financial highlights for Curis INC are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Curis INC?

Key executives at Curis INC are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Curis INC stock?

Risk factors for Curis INC (CRIS) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Curis INC?

Forward-looking statements and predictions from Curis INC are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Curis INC. Recent 10-K filing on Mar 24, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Curis INC on SEC EDGAR

Overview

Curis INC (CRIS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Mar 24, 2026: CURIS INC, a biotechnology company, reported a cash and cash equivalents balance of $5.1 million as of December 31, 2025. The company completed a private placement in January 2026, raising net proceeds of approximately $18.6 million to fund operations. CURIS is focused on developing emavusertib (CA-

Sentiment Summary

Across 29 filings, the sentiment breakdown is: 5 bearish, 23 neutral, 1 mixed. The dominant filing sentiment for Curis INC is neutral.

Filing Type Overview

Curis INC (CRIS) has filed 2 10-K, 1 8-K/A, 6 10-Q, 12 8-K, 1 S-1, 2 DEF 14A, 2 SC 13G/A, 3 SC 13G with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (29)

CURIS Nears Cash Crunch, Eyes Emavusertib for Accelerated Approval — 10-K · Mar 24, 2026 Risk: high
CURIS INC, a biotechnology company, reported a cash and cash equivalents balance of $5.1 million as of December 31, 2025. The company completed a private placem
8-K/A Filing — 8-K/A · Nov 13, 2025
Curis Narrows Losses Amid R&D Cuts, Raises Going Concern Doubts — 10-Q · Nov 6, 2025 Risk: high
CURIS INC reported a net loss of $7.729 million for the three months ended September 30, 2025, an improvement from the $10.092 million net loss in the same peri
Curis Inc. Faces Delisting Concerns — 8-K · Oct 24, 2025 Risk: high
Curis, Inc. filed an 8-K on October 24, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company, incorpora
Curis Inc. Faces Delisting Concerns — 8-K · Aug 22, 2025 Risk: high
Curis, Inc. filed an 8-K on August 22, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the effective date
Curis Files S-1 for Future Capital Raise, Signaling Funding Flexibility — S-1 · Aug 11, 2025 Risk: medium
CURIS INC (CRIS) filed an S-1 registration statement on August 8, 2025, for a delayed or continuous offering of securities under Rule 415, indicating a potentia
Curis Inc. Files 8-K: Other Events & Financials Reported — 8-K · Aug 8, 2025 Risk: medium
Curis, Inc. filed an 8-K on August 8, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific details about
Curis Narrows Q2 Loss Amidst Zero Revenue, Focuses on Pipeline — 10-Q · Aug 5, 2025 Risk: high
CURIS INC reported no revenue for the three and six months ended June 30, 2025, consistent with the prior year periods. The company posted a net loss of $25.3 m
Curis Inc. Files 8-K: Material Agreement, Equity Sales Reported — 8-K · Jul 2, 2025 Risk: medium
Curis, Inc. filed an 8-K on July 2, 2025, reporting on events as of July 1, 2025. The filing indicates an entry into a material definitive agreement, unregister
Curis Inc. Files 8-K: Corporate Governance and Shareholder Matters — 8-K · May 22, 2025 Risk: medium
Curis, Inc. filed an 8-K on May 22, 2025, reporting on several key events that occurred on May 20, 2025. These include material modifications to security holder
Curis Inc. Files Q1 2025 10-Q — 10-Q · May 6, 2025 Risk: medium
Curis Inc. filed its 10-Q for the period ending March 31, 2025. The company, based in Lexington, MA, reported on its financial status. Key financial data points
Curis Inc. Executive Compensation Details Revealed — DEF 14A · Apr 10, 2025 Risk: medium
Curis Inc. filed its DEF 14A on April 10, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information o
Curis Inc. Files 8-K on Financials — 8-K · Mar 31, 2025 Risk: low
Curis, Inc. filed an 8-K on March 31, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibit
Curis, Inc. Files 8-K with Material Agreements and Financial Updates — 8-K · Mar 28, 2025 Risk: medium
On March 28, 2025, Curis, Inc. filed an 8-K report detailing several key events. The company entered into a material definitive agreement, reported on its resul
Curis Inc. Faces Delisting Concerns — 8-K · Feb 27, 2025 Risk: high
Curis, Inc. filed an 8-K on February 27, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The earliest event reported was o
Curis Inc. Files Q3 2024 10-Q Report — 10-Q · Nov 14, 2024 Risk: medium
Curis Inc. reported its financial results for the period ending September 30, 2024. The company's filing covers the third quarter and the first nine months of t
SC 13G/A Filing — SC 13G/A · Nov 13, 2024
SC 13G Filing — SC 13G · Nov 1, 2024
Curis Inc. Amends Credit Agreement — 8-K · Oct 30, 2024 Risk: medium
On October 28, 2024, Curis, Inc. entered into a material definitive agreement, specifically a Second Amendment to the Second Amended and Restated Credit Agreeme
Curis Inc. Files 10-Q for Q2 2024 — 10-Q · Aug 1, 2024 Risk: medium
Curis Inc. filed its 10-Q for the period ending June 30, 2024. The company, located in Lexington, MA, is in the biological products sector. Key financial data a
Curis, Inc. Files 8-K with Key Corporate Updates — 8-K · May 23, 2024 Risk: medium
On May 21, 2024, Curis, Inc. filed an 8-K report detailing several significant events. These include material modifications to the rights of security holders, c
Curis, Inc. Files 8-K Report — 8-K · May 14, 2024 Risk: low
On May 14, 2024, Curis, Inc. filed an 8-K report to disclose other events and financial statements. The filing does not contain specific details on new material
Curis Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 7, 2024 Risk: low
CURIS INC (CRIS) filed a Quarterly Report (10-Q) with the SEC on May 7, 2024. Curis Inc. filed a 10-Q report for the period ending March 31, 2024. The filing co
SC 13G Filing — SC 13G · Apr 15, 2024
Curis, Inc. Announces 2024 Annual Meeting of Stockholders on May 21 — DEF 14A · Apr 10, 2024 Risk: low
CURIS INC (CRIS) filed a Proxy Statement (DEF 14A) with the SEC on April 10, 2024. Curis, Inc. will hold its annual meeting of stockholders virtually on May 21,
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
M28 Capital Management LP Takes 5.0% Stake in Curis Inc. — SC 13G · Feb 12, 2024 Risk: low
M28 Capital Management LP, a Delaware-based investment firm, reported owning 421,951 shares of Curis, Inc. common stock as of December 31, 2023. This represents
Curis, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 8, 2024 Risk: medium
CURIS INC (CRIS) filed a Annual Report (10-K) with the SEC on February 8, 2024. Curis, Inc. filed its 2023 Form 10-K on February 8, 2024, reporting on the fisca
Curis Files Routine 8-K on Jan 11, No Major News — 8-K · Jan 11, 2024
Curis, Inc. filed an 8-K on January 11, 2024, to report a current event. This filing is a standard procedural update, indicating no major financial or operation

Risk Profile

Risk Assessment: Of CRIS's 23 recent filings, 6 were flagged as high-risk, 12 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Curis INC's most recent 10-K filing (Mar 24, 2026):

Cash Position: $5.1 million

Key Executives

James E. Dentzer
Cynthia T. Mazareas, Esq.
Caroline Dotolo, Esq.
December 31, 2023

Industry Context

Curis Inc. operates in the highly competitive biotechnology sector, focusing on oncology drug development. The industry is characterized by significant R&D investment, long development cycles, and high failure rates. Companies often rely on targeted therapies for specific patient populations, with orphan drug designations playing a key role in incentivizing development for rare diseases.

Top Tags

Biotechnology (5) · financials (4) · 10-Q (4) · Oncology (3) · Clinical Trials (3) · delisting (3) · listing-standards (3) · regulatory-filing (3) · 8-k (3) · biotech (3)

Key Numbers

Cash and cash equivalents: $5.1 million — as of December 31, 2025, indicating severe liquidity constraints
Net proceeds from January 2026 PIPE Financing: $18.6 million — recent capital infusion to fund operations
Shares of common stock outstanding: 39,978,693 — as of March 20, 2026
Aggregate market value of common stock held by non-affiliates: $24.8 million — as of June 30, 2025
Potential patient number for CMA submission: 45 patients — may be sufficient for European Conditional Marketing Authorization for PCNSL
Net Loss (Q3 2025): $7.729M — Improved from $10.092M in Q3 2024
Net Loss (9M 2025): $26.938M — Improved from $33.771M in 9M 2024
Revenue (Q3 2025): $3.176M — Increased from $2.931M in Q3 2024
Revenue (9M 2025): $8.305M — Increased from $7.563M in 9M 2024
R&D Expenses (Q3 2025): $6.432M — Decreased 33.8% from $9.723M in Q3 2024
R&D Expenses (9M 2025): $22.429M — Decreased 24.3% from $29.594M in 9M 2024
Cash & Cash Equivalents (Sep 30, 2025): $9.051M — Decreased from $19.997M at Dec 31, 2024
Proceeds from Equity Offerings (9M 2025): $15.471M — Net cash provided by financing activities
Total Stockholders' Deficit (Sep 30, 2025): $14.691M — Increased from $5.998M at Dec 31, 2024
Net Loss Per Share (Q3 2025): $0.49 — Improved from $1.70 in Q3 2024

Forward-Looking Statements

{"claim":"M28 Capital Management LP will maintain or increase its stake in Curis, Inc. over the next 6-12 months.","entity":"M28 Capital Management LP","targetDate":"December 31, 2024","confidence":"medium"}
{"claim":"CURIS INC's revenue will remain highly dependent on Genentech Inc. in the near term.","entity":"CURIS INC","targetDate":"2024-12-31","confidence":"high"}
{"claim":"Any negative change in the relationship with Genentech Inc. could lead to a significant decline in CURIS INC's stock price.","entity":"CURIS INC","targetDate":"2024-12-31","confidence":"high"}

Related Companies

RHHBY · ROG.SW

Frequently Asked Questions

What are the latest SEC filings for Curis INC (CRIS)?

Curis INC has 29 recent SEC filings from Jan 2024 to Mar 2026, including 12 8-K, 6 10-Q, 3 SC 13G. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of CRIS filings?

Across 29 filings, the sentiment breakdown is: 5 bearish, 23 neutral, 1 mixed. The dominant sentiment is neutral.

Where can I find Curis INC SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Curis INC (CRIS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Curis INC?

Key financial highlights from Curis INC's most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for CRIS?

The investment thesis for CRIS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Curis INC?

Key executives identified across Curis INC's filings include James E. Dentzer, Cynthia T. Mazareas, Esq., Caroline Dotolo, Esq., December 31, 2023.

What are the main risk factors for Curis INC stock?

Of CRIS's 23 assessed filings, 6 were flagged high-risk, 12 medium-risk, and 5 low-risk.

What are recent predictions and forward guidance from Curis INC?

Recent forward-looking statements from Curis INC include guidance on {"claim":"M28 Capital Management LP will maintain or increase its stake in Curis, Inc. over the next 6-12 months.","enti and 2 other predictions.